The day of HSCT was designated day 0. Patients received MMF, cyclosporine and methotrexate as a triple immunosuppressive regimen for GVHD prophylaxis. The patients in our study were administered lyophilized powder of MMF for injection (Cellcept®, Roche Pharmaceuticals Ltd., Rochester, MI, USA, 0.5 g; Jianlin®, Shuanghe Pharmaceuticals Ltd., Hainan, China, 0.5 g) at a fixed dose of 500 mg every 12 h from day –9. IV cyclosporine was adjusted to maintain therapeutic levels of 150–350 ng/mL early after transplantation, and then administered orally when tolerated. Methotrexate at a dose of 15 mg/m2 was given intravenously on day 1, followed by 10 mg/m2 on days 3, 6 and 11.
Every patient received meropenem or imipenem as infection treatment, typically 1 g every 8 h, except for two patients who received meropenem 500 mg every 8 h or imipenem 500 mg every 6 h. Rifaximin 0.4 g twice daily was administered for gut decontamination, starting before CBP and MMF, and then continuously during MMF sampling. All patients received proton pump inhibitors across all data collection periods. In addition, all patients received antifungal and antiviral prophylaxis in accordance with standard practice at the institution.
Every patient received meropenem or imipenem as infection treatment, typically 1 g every 8 h, except for two patients who received meropenem 500 mg every 8 h or imipenem 500 mg every 6 h. Rifaximin 0.4 g twice daily was administered for gut decontamination, starting before CBP and MMF, and then continuously during MMF sampling. All patients received proton pump inhibitors across all data collection periods. In addition, all patients received antifungal and antiviral prophylaxis in accordance with standard practice at the institution.
